Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 149, Issue 10, Pages 1809-1816Publisher
WILEY
DOI: 10.1002/ijc.33733
Keywords
compassionate use; conflict of interest; expanded access
Categories
Funding
- Kosciuszko Foundation Fellowship
Ask authors/readers for more resources
The study assessed self-reported conflicts of interest in oncology expanded access studies and found that most authors disclosed financial conflicts, while nonfinancial conflicts were reported less. Financial conflicts were more likely to occur in studies with at least one center in the United States, while studies without industry funding were less likely to have positive conclusions about the treatments studied.
Expanded access is a treatment use of investigational drugs, biologicals or medical devices outside of clinical trials. The purpose of our study was to assess self-reported conflicts of interest (COIs) in oncology expanded access studies. One hundred fifty-eight oncology expanded access studies published from 2013 through 2020 were included. The pharmaceutical industry funded either completely or in part 94 studies (59.49%). The authors disclosed mostly financial COIs, while the number of the reported nonfinancial conflicts was relatively small (3528 and 57 COIs, respectively). The number of articles in which at least one author had a financial COI was 118 (74.68%). The most common financial COI types included advisory board membership/consulting (1471 COIs; 41.7%), followed by honoraria (570 COIs; 16.16%) and research funding (441 COIs; 12.5%). Logistic regression was performed to identify predictors of disclosing financial COIs and positive study's conclusions. On univariate analysis, financial COIs were more likely to occur in studies with at least one center located in the United States (odds ratio [OR], 5.62; 95% confidence interval [CI], 1.57-35.98; P = .02). We also found that positive conclusions about the studied treatments were less likely in studies without industry funding (OR, 0.26; CI, 0.08-0.77; P = .01). Most of the research on COIs in oncology performed to date focused on other types of studies, especially clinical trials. To our knowledge, our study is the first to evaluate COIs in oncology expanded access studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available